Navigation Links
Boehringer Ingelheim to present new data at ASCO annual meeting regarding its investigational compound afatinib in EGFR-mutation positive patients with advanced NSCLC
Date:5/25/2011

RIDGEFIELD, Conn., May 25 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. will present new phase Ib data at the 2011 American Society of Clinical Oncology (ASCO) annual meeting in Chicago (June 3-7) that indicates combining its investigational therapy afatinib (BIBW 2992) with cetuximab at the maximum tested dose controlled disease in all (n=22) treated epidermal growth factor receptor (EGFR)-mutation positive patients with non-small cell lung cancer (NSCLC) who developed acquired resistance to treatment with a reversible EGFR tyrosine kinase inhibitor (TKI). Researchers observed a tumor size reduction of up to 76 percent over a treatment period of up to five months.(1) The most common drug-related adverse events were rash and diarrhea, with three patients (11.5%) experiencing Grade 3 rash. Afatinib is an orally-administered irreversible inhibitor of the erbB family of receptor tyrosine kinases, specifically EGFR and HER2.  It is in late-stage development in advanced NSCLC and breast cancer.

Boehringer Ingelheim and QIAGEN are pleased that ASCO and the National Comprehensive Cancer Network (NCCN), two leading oncology organizations, recently recommended EGFR mutation testing for patients with metastatic or recurrent NSCLC.  These recommendations underscore the importance of genetic tumor testing to predict patient response to certain treatments, enabling personalized healthcare.  Boehringer Ingelheim has partnered with QIAGEN to develop a real-time polymerase chain reaction assay (real-time PCR) companion diagnostic test for afatinib that, if approved, could help physicians identify which patients may benefit from EGFR-targeted therapies.

"The ASCO and NCCN EGFR mutation testing recommendations reinforce the importance of identifying the appropriate NSCLC patients for clinical trials," said Christopher Corsico, M.D., M.P.H., Senior Vice President, Medicine and Regulatory, Boehringer Ingelheim Pharmaceuticals, Inc. "
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
2. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
3. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
4. Boehringer Ingelheim Unveils Diabetes Pipeline
5. Boehringer Ingelheim Animal Health Closes Deal to Acquire a Significant Portion of the Fort Dodge Animal Health Business From Pfizer
6. Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile
7. New Boehringer Ingelheim Science Quest Mobile Laboratory Brings Hands-On Science Education to Priority Connecticut Elementary Schools
8. Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010
9. -- Neurocrine Announces a Second Corporate Collaboration Within Twenty-Four Hours -- Neurocrine Biosciences Announces a Worldwide Collaboration With Boehringer Ingelheim to Research and Develop GPR119 Agonists for Type II Diabetes
10. Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes
11. Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 The consumer marketing playbook and ... sectors to better identify winning tools and techniques. ... with and understand consumers, as new technologies are ... purchasing decisions. According to recent ... area where organizations can observe a deep pool ...
(Date:7/11/2014)... 2014  Kindred Hospital Houston Northwest, with Wound ... of its new outpatient wound healing center.  The ... with chronic, hard to heal wounds. Chronic wounds ... amputation, lower leg wounds related to blood flow ... traumatic injury wounds which are complex and demonstrate ...
(Date:7/11/2014)... July 11, 2014  Veran Medical Technologies, ... today the positive, cost-effective final results for ... procedure. The SPiNPerc endobronchial percutaneous biopsy study ... approach to biopsy when a traditional bronchoscopic ... physicians experience positive financial outcomes when more ...
Breaking Medicine Technology:New Technologies Transforming Consumer Marketing Research Playbook 2Kindred Hospital Houston Northwest, With Wound Care Specialists, Opens Outpatient Wound Healing And Hyperbaric Center 2Veran Medical Publishes Lung Cancer Patient Management Study 2
... Scientific Presentations Detail Progress with VeraTag(TM) Assays in Breast ... ... (Nasdaq: MGRM ) today announced five posters to be,presented at the 30th ... - 16, 2007. Following are details for,each embargoed session:, -- Friday, ...
... Tainted Research Grant Applications Must Be Rejected, Consumer,Advocates ... More apparent,conflict of interest violations in applications for ... were revealed today and the,Foundation for Taxpayer and ... to be rejected., The latest improprieties were ...
Cached Medicine Technology:Monogram Announces Posters to be Presented at the 30th San Antonio Breast Cancer Symposium 2Monogram Announces Posters to be Presented at the 30th San Antonio Breast Cancer Symposium 3New Conflict of Interest Violations Revealed at California Stem Cell Institute 2New Conflict of Interest Violations Revealed at California Stem Cell Institute 3
(Date:7/13/2014)... American water storage systems market is estimated to grow from ... a CAGR of 21.0%, from 2013 to 2018. The water ... North America. The U.S. is experiencing high growth on account ... collection, and the increased spending on modernization and upgradation of ... in Canada, and is rising at a rapid pace in ...
(Date:7/13/2014)... July 13, 2014 The report ... Molybdenum, Iron), Form (Chelated & Non Chelated), Application ... - Global Trends and Forecast to 2018” defines ... an analysis and forecasting of the global value ... the driving and restraining factors for the global ...
(Date:7/13/2014)... Fuel additives are chemicals, which are added ... kerosene, and so on, in order to enhance their ... corrosion effects caused by fuels and improving the combustion ... provide economies of scale in the long run, but, ... of the fuel products. , The various fuel additive ...
(Date:7/13/2014)... MarketsandMarkets recently conducted a study on the ... rendering; Layout and Animation; Image Reconstruction]: Global Advancements, ... analyzes and studies the major market drivers, restraints, ... Europe, Middle East and Africa, Asia-Pacific and Latin ... of the 3D imaging market, providing an in-depth ...
(Date:7/13/2014)... HealthDay Reporter FRIDAY, July ... sensor for people with diabetes is being developed to measure ... researchers report. Scientists at Brown University in Providence, R.I., ... It uses light, metal and a special enzyme that changes ... diabetics have to prick their fingers to draw blood to ...
Breaking Medicine News(10 mins):Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 2Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 3Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 2Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 3Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 4Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 2Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 4Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 2Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 4Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 2Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 3
... of ... Haematology Business Assets, WAYNE, Pa., Nov. 13 Escalon Medical ... quarter ended,September 30, 2008., For the first quarter of fiscal ... in fiscal 2007. This,included product revenue of $8,669,000 for the first ...
... /PRNewswire-FirstCall/ - BELLUS Health Inc. (NASDAQ:,BLUS; TSX: BLU) announces ... Qualifications Staff of The NASDAQ Stock Market LLC (the,"Staff") ... The NASDAQ Global,Market to The NASDAQ Capital Market. The ... market on Friday, November 14, 2008. The Company will,continue ...
... RONKONKOMA, N.Y., Nov. 13 NBTY, Inc. (NYSE:,NTY) ... supplements, today announced that Arthur Rudolph, its Founder,and a ... pre-arranged stock,trading plan to sell a portion of his ... strategy of asset diversification and liquidity. The stock,trading plan ...
... Predictive medicine company,PreMD Inc. (TSX: PMD; PREMF.pk) ("PreMD" or the ... fiscal 2008 ended,September 30, 2008 ("Q3 2008")., During ... the PREVU* appeal is being reviewed by the FDA Commissioner,s ... the agreement with AstraZeneca has been terminated; - ...
... urging safe sex practices, study says , , THURSDAY, ... for pelvic inflammatory disease (PID) become highly vulnerable ... or months after treatment, researchers at Johns Hopkins ... the researchers, suggest that treating PID "with a ...
... Pharmos Corporation,(Nasdaq: PARS ) today announced that it ... 11, 2008 that the Company is not in,compliance with ... a minimum of $2,500,000 in stockholders, equity or,$35,000,000 market ... continuing operations for the most recently completed fiscal year ...
Cached Medicine News:Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 2Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 3Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 4Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 5Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 6Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 7Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 8Health News:BELLUS Health Announces Stock Listing Transfer from NASDAQ Global Market to NASDAQ Capital Market 2Health News:NBTY Founder Adopts Rule 10b5-1 Trading Plan 2Health News:PreMD Inc. Reports Third Quarter Results and Appoints New Chief Financial Officer 2Health News:PreMD Inc. Reports Third Quarter Results and Appoints New Chief Financial Officer 3Health News:PreMD Inc. Reports Third Quarter Results and Appoints New Chief Financial Officer 4Health News:PreMD Inc. Reports Third Quarter Results and Appoints New Chief Financial Officer 5Health News:PreMD Inc. Reports Third Quarter Results and Appoints New Chief Financial Officer 6Health News:PreMD Inc. Reports Third Quarter Results and Appoints New Chief Financial Officer 7Health News:PreMD Inc. Reports Third Quarter Results and Appoints New Chief Financial Officer 8Health News:PreMD Inc. Reports Third Quarter Results and Appoints New Chief Financial Officer 9Health News:PreMD Inc. Reports Third Quarter Results and Appoints New Chief Financial Officer 10Health News:PreMD Inc. Reports Third Quarter Results and Appoints New Chief Financial Officer 11Health News:PreMD Inc. Reports Third Quarter Results and Appoints New Chief Financial Officer 12Health News:PreMD Inc. Reports Third Quarter Results and Appoints New Chief Financial Officer 13Health News:Pelvic Inflammation Puts Girls at Risk for Repeat STIs 2Health News:Pharmos Corporation Announces Receipt of Nasdaq Noncompliance Letter 2
3 mm, 130 degree upwards cutting, detachable....
Sabre 180 is a powerful niche generator....
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
Medicine Products: